Plasmapheresis As A Novel Treatment Of Postural Tachycardia Syndrome: A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$97,081.00
Summary
We aim to conduct a randomized controlled trial to test our hypothesis that the removal of autoantibodies (through plasmapheresis) will reduce the severity of symptoms in patients with postural tachycardia syndrome. We will be measuring symptom scores, cardiovascular fitness on exercise testing, heart rate and blood pressure responses during valsalva and orthostatic stress as well as the metabolic profiles and presence of autoantibodies in the blood of patients participating in the trial.